Cite
HARVARD Citation
Ikeda, M. et al. (n.d.). 2356 Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment. European journal of cancer. pp. S454-. [Online].